improving the treatment of low-risk mds: luspatercept, treatment sequencing & disease classification
Published 1 year ago • 461 plays • Length 2:12Download video MP4
Download video MP3
Similar videos
-
11:33
treatment algorithm for low-risk mds
-
0:56
the promise of luspatercept for the treatment of lower-risk mds
-
11:53
the optimal treatment of lower risk mds
-
1:15
luspatercept for the treatment of patients with lower-risk mds and esa failure
-
3:38
a new set of treatment options for low-risk mds
-
7:54
patient/caregiver stories - living with mds
-
6:36
mds: low-risk disease treatment options
-
1:22:25
low-risk mds: can we prevent progression?
-
1:20
the current standard of care for patients with lower-risk mds
-
1:14
real-world treatment patterns of patients with low-risk mds reinitiating esas
-
2:11
new therapeutic options for low-risk mds
-
7:05
state-of-the-art treatment regimens for lr-mds
-
1:32
next-generation sequencing for low-risk mds
-
1:04
the current standard of care for mds-related cytopenias and how treatment strategies may evolve
-
3:08
the treatment protocol for higher risk mds
-
3:15
mds: treating high and low-risk disease
-
4:12
novel therapies in low-risk mds
-
0:48
an introduction to the maxilus study: the optimal dose of luspatercept in lr-mds
-
1:00
findings from the commands study and the approval of luspatercept for lower-risk mds
-
4:35
lower-risk mds in 2021: luspatercept, imetelstat & roxadustat
-
1:02
update on treatments for high- and low-risk mds
-
18:42
novel treatment strategies in low-risk mds: case study